Finasteride; tadalafil - Generic Drug Details
What are the generic sources for finasteride; tadalafil and what is the scope of patent protection?
Finasteride; tadalafil
is the generic ingredient in two branded drugs marketed by Blue Water Biotech, Novitium Pharma, and Zydus Lifesciences, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Summary for finasteride; tadalafil
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 3 |
| NDAs: | 3 |
| Clinical Trials: | 2 |
| DailyMed Link: | finasteride; tadalafil at DailyMed |
Recent Clinical Trials for finasteride; tadalafil
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt University Medical Center | Phase 2 |
| Eli Lilly and Company | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for finasteride; tadalafil
US Patents and Regulatory Information for finasteride; tadalafil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | FINASTERIDE AND TADALAFIL | finasteride; tadalafil | CAPSULE;ORAL | 218232-001 | Mar 15, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novitium Pharma | FINASTERIDE AND TADALAFIL | finasteride; tadalafil | CAPSULE;ORAL | 218499-001 | Mar 19, 2025 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Blue Water Biotech | ENTADFI | finasteride; tadalafil | CAPSULE;ORAL | 215423-001 | Dec 9, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Finasteride and Tadalafil Market Dynamics, Patent Expiry, Generic Competition, and Financial Trajectory
Finasteride and tadalafil are mature, chemically synthesized medicines with materially different market structures. Finasteride is dominated by low-cost generic volume across benign prostatic hyperplasia and androgenetic alopecia. Tadalafil retains greater commercial value because of its broader erectile dysfunction franchise, daily-use positioning, and additional indications, but generic entry has reduced branded pricing power.
Finasteride’s branded products, Proscar and Propecia, lost primary U.S. patent protection years ago. Tadalafil’s Cialis franchise retained meaningful protection into the late 2010s and early 2020s, delaying full generic erosion. Neither product faces biosimilar risk because both are small-molecule drugs regulated through abbreviated new drug applications, or ANDAs.
What are finasteride and tadalafil used for?
Finasteride inhibits type II 5-alpha-reductase and reduces conversion of testosterone to dihydrotestosterone. The 5 mg dose is approved for benign prostatic hyperplasia, while the 1 mg dose is approved for male pattern hair loss.
Tadalafil is a phosphodiesterase-5 inhibitor. Its FDA-approved uses include erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension under the Adcirca brand. Cialis is the principal tadalafil brand for erectile dysfunction and benign prostatic hyperplasia.[1][2]
| Drug | Principal brands | Key approved indications | Typical commercial dosage |
|---|---|---|---|
| Finasteride | Proscar, Propecia, generic finasteride | Benign prostatic hyperplasia; male pattern hair loss | 5 mg and 1 mg |
| Tadalafil | Cialis, Adcirca, generic tadalafil | Erectile dysfunction; benign prostatic hyperplasia; pulmonary arterial hypertension | 2.5 mg, 5 mg, 10 mg, 20 mg |
Finasteride is primarily a generic-volume product. Tadalafil remains a high-volume generic drug with residual brand and cash-pay demand, particularly in telehealth, online pharmacies, and direct-to-consumer channels.
How large are the finasteride and tadalafil markets?
Public market estimates differ because they may count prescriptions, retail sales, active ingredients, or branded and generic products. The durable commercial facts are clearer than individual market-research estimates.
Finasteride has a large prescription base but low revenue per prescription. Its 5 mg formulation benefits from chronic use in older male patients with benign prostatic hyperplasia. The 1 mg formulation has a separate demand pool in hair loss treatment, with substantial out-of-pocket and online prescribing activity.
Tadalafil has a higher revenue ceiling because:
- It is used for both episodic and daily erectile dysfunction treatment.
- The 5 mg daily dose supports chronic therapy.
- It has an approved benign prostatic hyperplasia indication.
- It has a separate pulmonary arterial hypertension franchise through Adcirca.
- Demand is less dependent on traditional urology prescribing because telehealth channels are significant.
The commercial comparison is summarized below.
| Metric | Finasteride | Tadalafil |
|---|---|---|
| Original innovator | Merck | Eli Lilly |
| Main branded products | Proscar, Propecia | Cialis, Adcirca |
| Generic availability | Broad and long established | Broad, following settlements and patent expiry |
| Main volume driver | Chronic BPH and hair-loss treatment | Erectile dysfunction, including daily therapy |
| Brand pricing power | Low | Reduced but historically stronger |
| Prescription channel | Primary care, urology, dermatology, telehealth | Primary care, urology, telehealth, specialty pharmacy for PAH |
| Biosimilar exposure | None | None |
| Principal competitive threat | Commodity generic pricing | Generic tadalafil, authorized generic supply, telehealth price competition |
When did finasteride lose exclusivity?
Finasteride’s main U.S. composition-of-matter protection expired before the current generic market formed.
Merck’s Proscar patent, U.S. Patent No. 4,760,071, expired in 2006. The Propecia patent, U.S. Patent No. 5,547,957, expired in 2013. These dates eliminated the principal patent barriers for the 5 mg and 1 mg products, respectively.[3][4]
| Product | Active ingredient | Principal patent | Approximate U.S. expiration | Current status |
|---|---|---|---|---|
| Proscar | Finasteride 5 mg | U.S. 4,760,071 | 2006 | Generic market |
| Propecia | Finasteride 1 mg | U.S. 5,547,957 | 2013 | Generic market |
The patent estate no longer provides a material basis for delaying ordinary generic entry. Any remaining intellectual-property value is more likely to involve manufacturing processes, formulations, packaging, trademarks, or data associated with particular commercial products rather than the core molecule.
What formulations are protected by finasteride patents?
The commercially important finasteride formulations are immediate-release oral tablets. The core product patents have expired, and ordinary tablet formulations are widely available from multiple manufacturers.
Potentially relevant secondary rights can include:
- Tablet composition and excipient combinations.
- Methods for treating hair loss or BPH.
- Manufacturing processes.
- Alternative delivery systems.
- Combination products.
These rights generally have less commercial reach than composition patents. A generic applicant can often design around a narrow formulation claim while preserving the active ingredient, dose, and therapeutic use.
When does tadalafil lose exclusivity?
Tadalafil’s core Cialis protection lasted materially longer than finasteride’s. Eli Lilly’s U.S. Patent No. 5,859,006 covered tadalafil and was listed in the FDA Orange Book for Cialis. The patent was extended by pediatric exclusivity and was widely associated with protection into 2020.[5][6]
Lilly also held method-of-use and related patents, including U.S. Patent No. 6,821,975. These patents supported litigation and settlement activity even after ANDA applicants challenged Cialis protection.
| Product | Principal patent family | Key commercial issue | Generic impact |
|---|---|---|---|
| Cialis | U.S. 5,859,006 | Core tadalafil protection, including pediatric extension | Delayed broad entry |
| Cialis | U.S. 6,821,975 and related use patents | Daily-use and therapeutic-use claims | Supported patent disputes and settlement terms |
| Adcirca | Tadalafil for pulmonary arterial hypertension | Separate brand and specialty distribution | Generic tadalafil creates substitution pressure |
Tadalafil generic entry began before all practical brand protection disappeared because Lilly reached settlements with ANDA applicants. Those agreements permitted generic tadalafil commercialization under defined timing and licensing terms. The result was a staged erosion rather than a single full-market launch.
Which companies challenged Cialis patents?
Generic-drug companies, including Teva Pharmaceuticals and Watson Laboratories, challenged Cialis patents through Paragraph IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed.
The litigation pattern followed the standard Hatch-Waxman structure:
- A generic applicant filed an ANDA for tadalafil tablets.
- The applicant notified Lilly of a Paragraph IV certification.
- Lilly filed patent-infringement litigation.
- The 30-month stay delayed FDA approval unless resolved earlier.
- Settlement agreements established permitted launch dates or licensed entry arrangements.
Lilly disclosed Cialis patent litigation and settlements in its SEC filings. Generic entry subsequently expanded, and tadalafil became available from multiple manufacturers in the United States.[6][7]
What is the Orange Book status of finasteride and tadalafil?
The FDA Orange Book identifies patents and exclusivity associated with approved drug products. For mature small-molecule products, Orange Book listings matter because they determine the patent certifications required in ANDAs.
Finasteride’s original Orange Book protection has expired. Generic finasteride applicants therefore compete primarily on manufacturing cost, supply reliability, wholesaler access, and dosage-form approvals.
Tadalafil’s Orange Book history was more commercially consequential. Cialis listings supported Paragraph IV challenges and delayed generic approval. Once the relevant patent and exclusivity barriers fell away, the commercial contest shifted from patent timing to pricing and distribution.[5]
An Orange Book listing does not by itself guarantee enforceability. Patent scope, claim construction, validity, infringement, settlement terms, and regulatory approval timing determine the actual entry risk.
What is the FDA regulatory status of finasteride and tadalafil?
Both medicines are FDA-approved small molecules. Generic versions are approved through the ANDA pathway, which requires the applicant to demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug.
| Regulatory issue | Finasteride | Tadalafil |
|---|---|---|
| FDA pathway for generics | ANDA | ANDA |
| Reference brands | Proscar and Propecia | Cialis and, for PAH, Adcirca |
| New-drug exclusivity relevance | Expired | Expired or commercially exhausted |
| Biosimilar pathway | Not applicable | Not applicable |
| Substitution | Generally available subject to state and payer rules | Generally available subject to state and payer rules |
The main regulatory risks are manufacturing deficiencies, product recalls, supply interruptions, labeling differences, and failure to maintain approved facilities. These risks affect all generic suppliers but do not recreate the original patent barrier.
How strong is the patent estate for finasteride compared with tadalafil?
Tadalafil has had the stronger historical patent estate. It benefited from later expiry, multiple listed patents, higher-value indications, and greater litigation activity. Finasteride is now a weak patent-driven business but remains commercially durable because of persistent demand.
| Patent-estate factor | Finasteride | Tadalafil |
|---|---|---|
| Core patent expiry | Long past | Primarily 2020-era protection |
| Method-of-use value | Limited after broad generic entry | Historically material for Cialis |
| Formulation value | Narrow and secondary | Secondary to core and use patents |
| Paragraph IV significance | Historical and largely exhausted | Major factor before generic launch |
| Current patent-based launch risk | Low | Low for ordinary generic tadalafil |
| Current commercial moat | Cost, supply, brand recognition | Brand, channel access, daily-use demand, specialty positioning |
For current investment analysis, tadalafil’s patent strength is historical rather than prospective. The relevant question is no longer whether generic entry is possible. It is how quickly prices, prescription share, and channel economics deteriorate.
What financial trajectory has finasteride followed?
Finasteride shifted from an innovator-led revenue model to a broad generic model.
Proscar generated branded revenue from chronic BPH treatment, while Propecia created a higher-margin dermatology and consumer-facing franchise. Once the principal patents expired, generic substitution sharply reduced brand pricing and market share. Merck has not maintained the same level of standalone financial disclosure for Proscar and Propecia that it provided during the products’ peak commercial years.
The current financial profile has four characteristics:
- High prescription persistence for BPH patients.
- Low average selling prices because many suppliers compete.
- Limited brand premium outside selected hair-loss channels.
- Revenue concentration in generic manufacturers rather than the original innovator.
Generic finasteride manufacturers can earn acceptable returns at scale, but the product is vulnerable to price compression, pharmacy-benefit-manager negotiations, and supply oversupply. The 1 mg hair-loss market can support better pricing in cash-pay and telehealth channels, although online competition limits the durability of that premium.
What financial trajectory has tadalafil followed?
Cialis was one of Eli Lilly’s major mature products. Its commercial peak was supported by brand recognition, strong physician awareness, daily-use differentiation, and broad erectile dysfunction demand. Lilly disclosed Cialis revenue in its annual reports before generic entry materially altered the product’s trajectory.[6]
The post-exclusivity trajectory has followed four stages:
| Stage | Financial effect |
|---|---|
| Pre-generic Cialis | High branded price and substantial operating margin |
| Initial licensed generic entry | Partial price erosion and controlled share loss |
| Broader generic competition | Lower net price and declining brand volume |
| Mature generic market | Commodity pricing, with residual brand and specialty demand |
Tadalafil retains more commercial segmentation than finasteride because different channels monetize the same molecule differently:
- Retail generic tadalafil competes primarily on price.
- Telehealth providers may bundle consultation, prescription, and fulfillment.
- Branded Cialis retains recognition among patients who prefer the reference brand.
- Adcirca serves pulmonary arterial hypertension patients through specialty channels.
- Daily 5 mg tadalafil has a distinct adherence and convenience proposition.
The molecule remains financially important at the aggregate market level, but the value has migrated from Lilly’s branded franchise to generic manufacturers, digital prescribing platforms, pharmacies, and distributors.
What generic entry risks exist for finasteride and tadalafil?
Finasteride generic launch risk
For finasteride, ordinary generic entry risk is largely realized. New entrants face commercial rather than legal barriers:
- Low unit prices.
- Established generic competitors.
- Limited differentiation among tablet products.
- Pharmacy and wholesaler concentration.
- Potential manufacturing and supply-chain volatility.
A new finasteride entrant needs low-cost production or a differentiated channel. Patent litigation is unlikely to provide a durable market barrier for standard 1 mg or 5 mg tablets.
Tadalafil generic launch risk
For tadalafil, legal risk has largely transitioned into commercial execution risk. A new supplier must manage:
- ANDA approval and labeling compliance.
- Patent-certification history.
- Competition from established manufacturers.
- Authorized-generic and licensed-generic supply.
- Channel access in retail, mail order, and telehealth.
- Pricing pressure from payer formularies.
- Potential competition across multiple approved strengths.
Tadalafil is more attractive than finasteride for suppliers that can secure differentiated distribution or specialty access. It is less attractive for an undifferentiated entrant competing solely on tablet price.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest for both medicines because neither requires biologic cell culture, complex delivery technology, or cold-chain distribution. The active ingredients are established small molecules, and the dosage forms are conventional oral tablets.
The main barriers are operational:
- API sourcing and qualification.
- Compliance with current good manufacturing practices.
- Bioequivalence testing.
- Reliable multi-site supply.
- Scale economics.
- Regulatory inspection readiness.
- Control of impurities and dissolution performance.
Intellectual-property barriers may remain for narrow formulations, fixed-dose combinations, or new delivery systems. Those rights do not generally prevent competition against standard finasteride or tadalafil tablets.
How does finasteride compare with tadalafil for investors and licensors?
Tadalafil offers the larger revenue pool and stronger historical patent record. Finasteride offers steadier demand and lower technical risk but has limited pricing power.
| Investment criterion | Finasteride | Tadalafil |
|---|---|---|
| Market maturity | Highly mature | Highly mature |
| Patent upside | Minimal | Minimal after generic entry |
| Demand stability | High | High, with discretionary sensitivity in ED |
| Pricing power | Low | Low to moderate by channel |
| Manufacturing complexity | Low | Low |
| Brand value | Narrow, strongest in hair loss | Stronger legacy brand value |
| Litigation exposure | Low currently | Historically significant, currently reduced |
| Licensing attractiveness | Channel or formulation-specific | Channel, specialty, or branded-generic specific |
| Revenue growth potential | Limited | Limited for commodity generic, higher for differentiated channels |
The best commercial opportunities are unlikely to come from a new standard tablet. They are more likely to involve telehealth integration, specialty distribution, combination products, adherence programs, or geographic markets where generic penetration remains incomplete.
What licensing deals and settlement agreements affected tadalafil?
Cialis patent settlements with generic applicants enabled controlled entry before or around the end of the patent term. These arrangements reduced uncertainty for both Lilly and generic manufacturers while preserving some period of branded revenue protection.
The economic effect was a transfer from litigation delay to scheduled competition. Settlement terms can influence:
- The earliest generic launch date.
- Whether entry is licensed or at risk.
- Whether an authorized generic is supplied.
- The number of competing manufacturers at launch.
- The speed of price erosion.
For finasteride, the most important licensing and settlement events are historical because generic competition has existed for many years. Current licensing value is more likely to relate to distribution, private-label supply, or specialized formulations.
What litigation status affects finasteride and tadalafil?
Current litigation risk for ordinary finasteride and tadalafil tablets is substantially lower than it was before generic entry. The principal disputes have shifted toward:
- Product liability claims.
- Advertising and labeling disputes.
- Manufacturing and quality actions.
- Patent claims covering new formulations or combinations.
- Contract disputes involving supply and distribution.
- Channel-related competition and antitrust issues.
Finasteride has faced product-liability scrutiny concerning sexual, reproductive, and psychiatric adverse effects. Tadalafil litigation has more commonly involved patent disputes, generic entry, labeling, and product-liability allegations. These matters can affect legal reserves and labeling strategy even when they do not block generic competition.
What are the likely generic launch scenarios?
Finasteride
The base case is continued price erosion with stable prescription demand. Market share remains distributed across numerous generic suppliers. A new entrant can gain volume through a low-cost manufacturing position, but sustained margin expansion is unlikely.
Tadalafil
The base case is continued generic share growth with residual Cialis demand. Prices remain higher in telehealth and cash-pay channels than in reimbursed retail pharmacy, but competition is increasing in both settings.
Three commercial outcomes are plausible:
- Commodity generic tadalafil dominates reimbursed retail prescriptions.
- Cialis retains a smaller premium segment based on patient preference and brand recognition.
- Telehealth providers capture margin through bundled services rather than the tablet itself.
Key Takeaways
- Finasteride is a mature, low-price generic market with stable demand and limited patent value.
- Proscar’s primary U.S. patent expired in 2006; Propecia’s primary U.S. patent expired in 2013.
- Tadalafil had a stronger and later-expiring patent estate, with Cialis protection extending into the 2020-era period.
- Paragraph IV challenges and settlements shaped the timing of generic tadalafil entry.
- Neither drug faces biosimilar competition because both are small molecules.
- Tadalafil has the larger commercial opportunity, but generic competition has transferred value away from Eli Lilly.
- Finasteride’s strongest remaining commercial niches are hair-loss treatment, telehealth, and private-pay channels.
- Future value is more likely to come from distribution, specialty access, formulations, and service integration than from core-molecule patents.
- Standard finasteride and tadalafil tablets face low current patent-based launch risk and high price competition.
FAQs
Is finasteride still profitable after patent expiry?
Yes, but profitability depends on manufacturing scale, supply reliability, and channel access. The original branded economics have largely disappeared, while generic suppliers earn lower margins on persistent prescription volume.
Does tadalafil have more commercial value than finasteride?
Yes. Tadalafil has broader indication coverage, stronger historical brand equity, a larger erectile dysfunction market, and more opportunities in daily-use and telehealth channels. Its generic margins are still under pressure.
Can a company obtain a new patent for tadalafil?
A company may obtain patents for a novel formulation, combination, delivery system, or manufacturing process if the invention satisfies patentability requirements. A new patent would not automatically restore exclusivity for standard tadalafil tablets.
Are Propecia and Cialis still protected by FDA exclusivity?
Their principal commercial exclusivity periods have expired. Current market protection depends on residual trademarks, brand demand, formulation rights, labeling, distribution, and commercial execution rather than original FDA exclusivity.
Are finasteride and tadalafil interchangeable?
No. They have different mechanisms, approved uses, dosing, safety profiles, and prescribing requirements. Finasteride reduces dihydrotestosterone production, while tadalafil inhibits phosphodiesterase-5.
References
- U.S. Food and Drug Administration. (2024). Propecia (finasteride) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Cialis (tadalafil) prescribing information. https://www.accessdata.fda.gov
- U.S. Patent No. 4,760,071. (1988). 5-alpha-androstane-3,17-dione derivatives. United States Patent and Trademark Office.
- U.S. Patent No. 5,547,957. (1996). Treatment of androgenic alopecia with 5-alpha-reductase inhibitors. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- Eli Lilly and Company. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.lilly.com
- Eli Lilly and Company. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.lilly.com
More… ↓
